



## Alzinova files patent application for the ALZ-201 antibody

**Alzinova AB (publ) ("Alzinova" or the "Company"), announces that the Company has filed a new patent application for a further developed form of the Company's monoclonal antibody ALZ-201. The patent application is part of Alzinova's strategic development of the patent portfolio for the Company's pharmaceutical candidates.**

Alzinova has recently filed a new patent application for a further developed form of the Company's monoclonal antibody ALZ-201. If the Company receives approval of the patent, the expected patent term would extend to at least 2044. Alzinova is continuously working on its intellectual property strategy and the application is an important part of the further development of the patent portfolio for the Company's pharmaceutical candidates.

*"The patent strategy and application are important parts of our efforts to position Alzinova as a leading actor in the development of treatments for Alzheimer's disease. We work continuously to strengthen our patent portfolio, which is also essential for future partner discussions",* comments CEO Kristina Torfgård.

### **More about ALZ-201**

ALZ-201 is a monoclonal antibody developed to specifically target and neutralize the toxic forms of the peptide amyloid-beta-42 ("A $\beta$ 42"), so-called oligomers, which are considered to be the underlying cause of Alzheimer's disease. The ALZ-201 antibody does not bind to other, harmless, forms of amyloid-beta such as fibrils and plaques as proven in pre-clinical studies on human material. The pre-clinical results indicate that it is a small amount of A $\beta$ 42 oligomers that account for the main toxic effect in Alzheimer's disease, and that specificity for this form is probably necessary to obtain a good therapeutic effect of an antibody treatment. Alzinova is currently developing a humanized version of ALZ-201 for Phase 1 clinical trials in patients with Alzheimer's disease. These studies are planned to start in 2024. The Company's research shows that both ALZ-201 and the vaccine ALZ-101 have best-in-class potential, and clinical results from other players in the field support the Company's strategy.

### **For more information, please contact:**

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*



### **About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

### **Attachments**

**Alzinova files patent application for the ALZ-201 antibody**